Celyad Oncology SA (NASDAQ:CYAD – Get Rating)’s stock price crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.88 and traded as low as $1.84. Celyad Oncology shares last traded at $1.84, with a volume of 9,089 shares traded.
Celyad Oncology Stock Up 2.7 %
The company has a current ratio of 1.71, a quick ratio of 2.58 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average of $1.88 and a 200-day moving average of $2.01.
About Celyad Oncology
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.
Read More
Receive News & Ratings for Celyad Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Celyad Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.
Read more here: Source link
